semaglutide cardiovascular outcomes 2025 news ACC 2025: Oral Reduces Events by 14% at 4 Years SOUL trial shows oral semaglutide

To ensure safety and replicate these results, medical supervision and strict adherence to administration protocols are crucial

Safety depends on the compound, dose, route, and product purity

A bloated belly does tend to SHOW more after pregnancy, even if you arent actually bloating more

It is the first time any obesity medication has reached 30%+ average weight loss in a Phase 3 trial

Novo Nordisks Wegovy pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America

Type 2 diabetes have experienced a significant growth in 2023 and expected to dominate the market in the forecast period, due to a rise in the number of diabetic patients